Skip to main content
SpringerLink
Log in

Schizophrene Psychosen

  • Chapter
  • First Online:
Psychiatrie, Psychosomatik, Psychotherapie

Part of the book series: Springer Reference Medizin ((SRM))

Zusammenfassung

Schizophrene Psychosen sind gekennzeichnet durch charakteristische, symptomatisch oft sehr vielgestaltige psychopathologische Querschnittsbilder mit Wahn, Halluzinationen, formalen Denkstörungen, Ich-Störungen, Affektstörungen und psychomotorischen Störungen. Der Verlauf ist heterogen und reicht von einer vollständigen Remission der Symptome bis zu einem chronischen Residualsyndrom. Die meisten Patienten erleben rezidivierende Erkrankungsepisoden. Die Ätiologie der Schizophrenie gilt als multifaktoriell. Es liegen heute vielfältige Befunde zu biologischen und psychosozialen Auffälligkeiten vor, wobei häufig unklar ist, ob diese die Störung mitbegründen oder ein Ergebnis ihres Verlaufs sind, am ehesten beides. In der Akutphase, der Postakutphase sowie zur Rezidivprophylaxe einer schizophrenen Psychose kommen antipsychotisch wirksame Medikamente zum Einsatz, die eine wichtige Säule der Therapie darstellen. Zusätzlich sollten alle Patienten im Rahmen ihrer Erkrankung eine kognitive Verhaltenstherapie erhalten. Neuere psychotherapeutische und psychosoziale Interventionen haben zuletzt weitere Evidenz für die Wirksamkeit gewonnen und spielen von Anfang an bei der Symptombehandlung als auch im weiteren Verlauf bei der Krankheitsverarbeitung sowie beim Erhalt des Funktionsniveaus als zusätzliche therapeutische Säule eine wesentliche Rolle. Neurostimulationsverfahren wie die Elektrokonvulsionsbehandlung oder neuere Stimulationsverfahren werden v. a. in therapieresistenten Fällen eingesetzt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228–1235

    Article  CAS  PubMed  Google Scholar 

  • Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22–31

    CAS  PubMed  Google Scholar 

  • Andreasen NC (1982) Negative syndromes in schizophrenia: definition and reliability. Arch Gen Psychiatry 39:784–788

    Article  CAS  PubMed  Google Scholar 

  • Andreasen NC, Carpenter WT Jr, Kane JM et al (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449

    Article  PubMed  Google Scholar 

  • Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (11):CD006633. doi:10.1002/14651858.CD006633.pub2

  • Baldessarini RJ (1988) A summary of current knowledge of tardive dyskinesia. Encephale 14 Spec No:263–268

    Google Scholar 

  • Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 3(2):115–122

    Article  CAS  PubMed  Google Scholar 

  • Barch DM, Ceaser A (2012) Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci 16(1):27–34. doi:10.1016/j.tics.2011.11.015. Epub 12.12.2011

    Article  PubMed  Google Scholar 

  • Benes FM (2011) Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders. Neuropharmacology 60(7–8):1232–1242

    Article  CAS  PubMed  Google Scholar 

  • Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991) Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48(11):996–1001

    Article  CAS  PubMed  Google Scholar 

  • Benkert O, Hippius H (Hrsg) (2015) Kompendium der psychiatrischen Pharmakotherapie. Springer, Heidelberg

    Google Scholar 

  • Bogerts B, Meertz E, Schönfeldt-Bausch R (1985) Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 42(8):784–791

    Article  CAS  PubMed  Google Scholar 

  • Bottlender R, Möller HJ (2003) The impact of duration of untreated psychosis on short- and long-term outcome in schizophrenia. Curr Opin Psychiatry 16(Suppl 2):39–43

    Article  Google Scholar 

  • Bottlender R, Strauss A, Möller HJ (2000) Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophr Res 44:145–150

    Article  CAS  PubMed  Google Scholar 

  • Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E (2012) Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry 169(7):719–724. doi:10.1176/appi.ajp.2012.11071091

    Article  PubMed  Google Scholar 

  • Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT) (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93. doi:10.1093/schbul/sbp116. Epub 02.12.2009

    Article  PubMed  Google Scholar 

  • Bunney BS (1992) Clozapine: a hypothesised mechanism for its unique clinical profile. Br J Psychiatry Suppl 17:17–21

    Google Scholar 

  • Calton T, Ferriter M, Huband N, Spandler H (2008) A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull 34(1):181–192. Epub 14.06.2007

    Article  PubMed  Google Scholar 

  • Cannon M, Jones PB, Murray RM (2002) Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 159(7):1080–1092

    Article  PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Article  CAS  Google Scholar 

  • Carpenter WT Jr, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11(3):440–452

    Article  PubMed  Google Scholar 

  • Carpenter WT, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578–583

    Article  PubMed  Google Scholar 

  • Caspi A, Moffitt TE (2006) Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7(7):583–590

    Article  CAS  PubMed  Google Scholar 

  • Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, Taurisano P, Romano R, Masellis R, Blasi G, Morgan C, Aitchison K, Mondelli V, Luzi S, Kolliakou A, David A, Murray RM, Bertolino A, Di Forti M (2015) Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull 41(5):1171–1182

    Article  PubMed  PubMed Central  Google Scholar 

  • Correll CU, De Hert M (2013) Antipsychotics for acute schizophrenia: making choices. Lancet 382(9896):919–920

    Article  PubMed  Google Scholar 

  • Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425

    Article  PubMed  Google Scholar 

  • Correll CU, Rummel-Kluge C, Corves C et al (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443–457

    Article  PubMed  Google Scholar 

  • Correll CU, Detraux J, De Lepeleire J, De Hert M (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14(2):119–136

    Article  PubMed  PubMed Central  Google Scholar 

  • Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J (2015) Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol Aug 25(8):1158–1166

    Article  CAS  Google Scholar 

  • Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63–74. doi:10.1016/S1474-4422(10)70253-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166(6):675–682. doi:10.1176/appi.ajp.2008.08060806. Epub 15.04.2009

    Article  PubMed  Google Scholar 

  • Davies G, Welham J, Chant D, Torrey EF, McGrath J (2003) A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull 29(3):587–593

    Article  PubMed  Google Scholar 

  • Davis KL, Kahn RS, Grant K, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486

    Article  CAS  PubMed  Google Scholar 

  • De Fazio P, Gaetano R, Caroleo M, Cerminara G, Maida F, Bruno A, Muscatello MR, Moreno MJ, Russo E, Segura-García C (2015) Rare and very rare adverse effects of clozapine. Neuropsychiatr Dis Treat 11:1995–2003. doi:10.2147/NDT.S83989. eCollection 2015

    Article  PubMed  PubMed Central  Google Scholar 

  • De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ (2009) Cardiovascular disease and diabetes in peoplewith severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society. Eur Psychiatry 24(6):412–424

    Article  PubMed  Google Scholar 

  • De Hert M, Dekker JM, Wood D et al (2010) Eine Konsensus-Erklärung der European Psychiatric Association (EPA) zu kardiovaskulären Erkrankungen und Diabetes bei Patienten mit einer schweren psychischen Erkrankung. Unterstützt von der European Association for the Study of Diabetes (EASD) und der European Society of Cardiology (ESC). Psychopharmakotherapie 17:3–13

    Google Scholar 

  • De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM et al (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10(2):138–151

    Article  PubMed  Google Scholar 

  • Deister A (1994) Subtypen schizophrener Psychosen. Ein Vergleich verschiedener diagnostischer Systeme unter besonderer Berücksichtigung des Langzeitverlaufs. Habilitationsschrift, Rheinische Friedrich-Wilhelms-Universität Bonn

    Google Scholar 

  • Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S (2015) Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 166(1–3):187–193. doi:10.1016/j.schres.2015.04.024. Epub 23.05.2015

    Article  PubMed  Google Scholar 

  • Donnelly L, Rathbone J, Adams CE (2013) Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev 8:CD001951. doi:10.1002/14651858.CD001951.pub2

    Google Scholar 

  • Drake RE, Mueser KT (2000) Psychosocial approaches to dual diagnosis. Schizophr Bull 26(1):105–118

    Article  CAS  PubMed  Google Scholar 

  • Essali A, Al-Haj Haasan N, Li C, Rathbone J (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (1):CD000059. doi:10.1002/14651858.CD000059.pub2

  • Essock SM, Frisman LK, Covell NH, Hargreaves WA (2000) Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 57(10):987–994

    Article  CAS  PubMed  Google Scholar 

  • Exner C, Lincoln T (2012) Neuropsychologie der Schizophrenie. Hogrefe, Göttingen

    Google Scholar 

  • Falkai P (Hrsg) (2013) DGPPN S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Springer, Heidelberg

    Google Scholar 

  • Falkai P (Hrsg) (2016) Praxishandbuch Schizophrenie. Diagnostik, therapie, Versorgungstrukturen. Elsevier Verlag, München

    Google Scholar 

  • Falkai P, Schneider-Axmann T, Honer WG (2000) Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality. Biol Psychiatry 47(11):937–943

    Article  CAS  PubMed  Google Scholar 

  • Falkai P, Rossner MJ, Schulze TG, Hasan A, Brzózka MM, Malchow B, Honer WG, Schmitt A (2015) Kraepelin revisited: schizophrenia from degeneration to failed regeneration. Mol Psychiatry 20(6):671–676

    Article  CAS  PubMed  Google Scholar 

  • Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Article  CAS  PubMed  Google Scholar 

  • Farde L, Nordström AL, Wiesel FA et al (1992) Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patient treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538–544

    Article  CAS  PubMed  Google Scholar 

  • Fleischhacker W, Németh G, Laszlovszky I, Czobor P, Szatmári B, Szalai E, Barabássy Á, Harsányi J, Debelle M, Durgam S, Bitter I, Kahn R (2016) Cariprazine as monotherapy for the treatment of predominant negative symptoms of patients with schizophrenia: a double-blind, active comparator-controlled phase-3 trial. npj Schizophrenia 2, 16010. doi:10.1038/npjschz.2016.10

    Google Scholar 

  • Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37(8):1680–1691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gaebel W (2012) Status of psychotic disorders in ICD-11. Schizophr Bull 38(5):895–898. doi:10.1093/schbul/sbs104

    Article  PubMed  PubMed Central  Google Scholar 

  • Gaebel W, Falkai P, Weinmann S, Wobrock T (2006) In: Deutsche Gesellschaft für Psychiatrie PuNH (Hrsg) S3-Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1, Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt

    Google Scholar 

  • Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M et al (2007) Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68:1763–1774

    Article  CAS  PubMed  Google Scholar 

  • Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79(7):549–556. doi:10.1016/j.biopsych.2015.08.001. Epub 12.08.2015

    Article  PubMed  Google Scholar 

  • Galderisi S, Merlotti E, Mucci A (2015) Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci 265(7):543–558

    Article  PubMed  Google Scholar 

  • Gentile S (2010) Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 36(3):518–544

    Article  PubMed  Google Scholar 

  • Großimlinghaus I, Falkai P, Gaebel W, Janssen B, Reich-Erkelenz D, Wobrock T, Zielasek J (2013) Entwicklungsprozess der DGPPN - Qualitätsindikatoren. Nervenarzt 84(3):350–365

    Google Scholar 

  • Gustavsson A et al (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:718–779

    Article  CAS  PubMed  Google Scholar 

  • Häfner H (1993b) What is schizophrenia? Neurol Psychopharmacol Brain Res 2:36–52

    Google Scholar 

  • Häfner H (1995) Was ist Schizophrenie? Fischer, Stuttgart, S 1–56

    Google Scholar 

  • Häfner H, Riecher A, Maurer K et al (1991) Geschlechtsunterschiede bei schizophrenen Erkrankungen. Fortschr Neurol Psychiatr 59:343–360

    Article  PubMed  Google Scholar 

  • Häfner H, Reicher-Rössler A, Maurer K et al (1992) First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 242:109–118

    Article  PubMed  Google Scholar 

  • Hagberg H, Gressens P, Mallard C (2012) Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 71(4):444–457

    Article  PubMed  Google Scholar 

  • Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS (2013) Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39(5):1129–1138

    Article  PubMed  Google Scholar 

  • Hamann J, Loh A, Kasper J et al (2006) Implikationen des Modells des „Shared Decision Making“ für Psychiatrie und Neurologie. Nervenarzt 77:1071–1078

    Article  CAS  PubMed  Google Scholar 

  • Harrigan EP, Miceli JJ, Anziano R et al (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psyschopharmacol 24:62–69

    Article  CAS  Google Scholar 

  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia (2012) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13(5):318–378

    Article  PubMed  Google Scholar 

  • Hasan A, Wobrock T, Gaebel W, Janssen B, Zielasek J, Falkai P, Germany Society of Psychotherapy and Psychosomatics (DGPPN), German Association of Psychiatry (2013a) National and international schizophrenia guidelines. Update 2013 regarding recommendations about antipsychotic pharmacotherapy. Nervenarzt 84(11):1359–1360, 1362–1364, 1366–1368

    Article  CAS  PubMed  Google Scholar 

  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia (2013b) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14(1):2–44

    Article  PubMed  Google Scholar 

  • Hasan A, Malchow B, Falkai P, Schmitt A (2014) The glutamate hypothesis of schizophrenia. Fortschr Neurol Psychiatr 82(8):447–456

    Article  CAS  PubMed  Google Scholar 

  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015a) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16(3):142–170. doi:10.3109/15622975.2015.1009163

    Article  PubMed  Google Scholar 

  • Hasan A, Wobrock T, Palm U, Strube W, Padberg F, Falkai P, Fallgatter A, Plewnia C (2015b) Hirnstimulationsverfahren zur Behandlung schizophrener Psychosen. Nervenarzt 86(12):1481–1491

    Google Scholar 

  • Hasan A, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Karch S, Schneider-Axmann T, Falkai P, Wobrock T (2016) Cognitive effects of high-frequency rTMS in schizophrenia patients with predominant negative symptoms: results from a multicenter randomized sham-controlled trial. Schizophr Bull 42(3):608–618. doi:10.1093/schbul/sbv142. Epub 03.10.2015

    Article  PubMed  Google Scholar 

  • Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA (2008) Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 165(4):479–489

    Article  PubMed  PubMed Central  Google Scholar 

  • Heres S, Cirjaliu DM, Dehelean L, Matei VP, Podea DM, Sima D, Stecher L, Leucht S (2015) The SWITCH study: rationale and design of the trial. Eur Arch Psychiatry Clin Neurosci 266(6):513–21

    Google Scholar 

  • Hill M (2015) Perspective: be clear about the real risks. Nature 525(7570):14

    Article  CAS  Google Scholar 

  • Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL (2003) Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 53(12):1075–1085

    Article  CAS  PubMed  Google Scholar 

  • Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull 35(3):549–562

    Article  PubMed  PubMed Central  Google Scholar 

  • Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69(8):776–786

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huber G (1983) Das Konzept substratnaher Basis-Symptome und seine Bedeutung für Theorie und Therapie schizophrener Erkrankungen. Nervenarzt 54:23–32

    CAS  PubMed  Google Scholar 

  • Huber G (1994) Psychiatrie. Lehrbuch für Studierende und Ärzte, 5. Aufl. Schattauer, Stuttgart/New York

    Google Scholar 

  • Jackson JH (1889) On postepileptic states: a contribution to the comparative study of insanities. J Ment Sci 34:490–500

    Google Scholar 

  • Jäger M, Riedel M, Messer T et al (2007) Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257:47–53

    Article  PubMed  Google Scholar 

  • Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 38(5):958–966

    Article  PubMed  PubMed Central  Google Scholar 

  • Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079

    Article  CAS  PubMed  Google Scholar 

  • Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE, EUFEST Study Group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085–1097. doi:10.1016/S0140-6736(08)60486-9

    Article  CAS  PubMed  Google Scholar 

  • Kambeitz J, Koutsouleris N (2014) Neuroimaging in psychiatry: multivariate analysis techniques for diagnosis and prognosis. Nervenarzt 85(6):714–719

    Article  CAS  PubMed  Google Scholar 

  • Kambeitz J, Abi-Dargham A, Kapur S, Howes OD (2014) Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry 204(6):420–429

    Article  PubMed  Google Scholar 

  • Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, Falkai P, Koutsouleris N (2015) Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. Neuropsychopharmacology 40(7):1742–1751

    Article  PubMed  PubMed Central  Google Scholar 

  • Kane JM, Woerner M, Borenstein M et al (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258

    CAS  PubMed  Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24(1):62–67

    CAS  PubMed  Google Scholar 

  • Kane JM, Leucht S, Carpenter D et al (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(Suppl 12):5–19

    PubMed  Google Scholar 

  • Kasper S, Möller HJ, Hale A (2010) The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 260:59–68

    Article  PubMed  Google Scholar 

  • Kempton MJ, Stahl D, Williams SC, DeLisi LE (2010) Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res 120(1–3):54–62

    Article  PubMed  Google Scholar 

  • Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB (2012) Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res 139(1–3):161–168

    Article  PubMed  PubMed Central  Google Scholar 

  • Khandaker GM, Zimbron J, Lewis G, Jones PB (2013) Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 43(2):239–257

    Article  CAS  PubMed  Google Scholar 

  • Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40(1):192–213

    Article  PubMed  Google Scholar 

  • Klosterkötter J (1988) Basissymptome und Endphänomene der Schizophrenie. Eine empirische Untersuchung der psychopathologischen Übergangsreihen zwischen defizitären und produktiven Schizophrenie-Symptomen. Springer, Berlin/Heidelberg/New York/Tokio

    Google Scholar 

  • Klosterkötter J (2006) Jeder Schizophreniekranke sollte so früh wie möglich behandelt werden. Psychiatr Prax 33:106–107

    Google Scholar 

  • Klosterkötter J (2014) Prediction of psychoses. Nervenarzt 85(10):1238–1248

    Article  PubMed  Google Scholar 

  • Klosterkötter J, Albers M (1994) Klinische Differential-Diagnostik schizophrener Minussymptomatik. In: Möller HJ, Laux G (Hrsg) Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Wien/New York, S 1–13

    Google Scholar 

  • Klosterkötter J, Hellmich M, Schutze-Lutter F (2000) Ist die Diagnose schizophrener Störungen schon in der initialen Prodromalphase vor der psychotischen Erstmanifestation möglich? Fortschr Neurol Psychiatr 68(Suppl 1):13–21

    Google Scholar 

  • Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164

    Article  PubMed  Google Scholar 

  • Koutsouleris N, Gaser C, Jäger M, Bottlender R, Frodl T, Holzinger S, Schmitt GJ, Zetzsche T, Burgermeister B, Scheuerecker J, Born C, Reiser M, Möller HJ, Meisenzahl EM (2008) Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. Neuroimage 39(4):1600–1612. Epub 01.11.2007

    Article  PubMed  Google Scholar 

  • Koutsouleris N, Davatzikos C, Borgwardt S, Gaser C, Bottlender R, Frodl T, Falkai P, Riecher-Rössler A, Möller HJ, Reiser M, Pantelis C, Meisenzahl E (2014) Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders. Schizophr Bull 40(5):1140–1153

    Article  PubMed  Google Scholar 

  • Koutsouleris N, Meisenzahl EM, Borgwardt S, Riecher-Rössler A, Frodl T, Kambeitz J, Köhler Y, Falkai P, Möller HJ, Reiser M, Davatzikos C (2015) Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain 138(Pt 7):2059–2073. doi:10.1093/brain/awv111. Epub 01.05.2015

    Article  PubMed  PubMed Central  Google Scholar 

  • Kulhara P, Shah R, Grover S (2009) Is the course and outcome of schizophrenia better in the ‚developing‘ world? Asian J Psychiatr 2(2):55–62

    Article  PubMed  Google Scholar 

  • Laan W, Smeets H, de Wit NJ, Kahn RS, Grobbee DE, Burger H (2009) Glucocorticosteroids associated with a decreased risk of psychosis. J Clin Psychopharmacol 29(3):288–290. doi:10.1097/JCP.0b013e3181a44575

    Article  CAS  PubMed  Google Scholar 

  • Lally J, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224. doi:10.1016/j.schres.2016.01.024. Epub 27.01.2016

    Article  PubMed  Google Scholar 

  • Lambert M, Naber D (2004) Current issues in schizophrenia; overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18(Suppl 2):5–17

    Article  PubMed  Google Scholar 

  • Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB (2009) Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry Jul 66(7):713–720. pubmed/19581562

    Google Scholar 

  • Laursen TM, Munk-Olsen T, Gasse C (2011) Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One 6(9):e24597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO et al (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1–56

    Article  PubMed  Google Scholar 

  • Leucht S (2014) Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 75(Suppl 1):8–14

    Article  PubMed  Google Scholar 

  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009b) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14(4):429–447. doi:10.1038/sj.mp.4002136. Epub 08.01.2008

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071. doi:10.1016/S0140-6736(12)60239-6. Epub 03.05.2012

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962. doi:10.1016/S0140-6736(13)60733-3. Epub 27.06.2013

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2):314–326. doi:10.1093/schbul/sbu001. Epub 03.02.2014

    Article  PubMed  PubMed Central  Google Scholar 

  • Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, Geddes J, Davis JM (2015) Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 41(6):1397–1402. doi:10.1093/schbul/sbv037. Epub 03.04.2015

    Article  PubMed  PubMed Central  Google Scholar 

  • Lewis DA (2009) Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia. Dialogues Clin Neurosci 11(3):269–280

    PubMed  PubMed Central  Google Scholar 

  • Lewis SW, Barnes TR, Davies L et al (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32(4):715–723

    Article  PubMed  PubMed Central  Google Scholar 

  • Leypoldt F, Wandinger KP (2014) Paraneoplastic neurological syndromes. Clin Exp Immunol 175(3):336–348. doi:10.1111/cei.12185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lieberman JA, Tollefson GD, Charles C et al (2005) Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62:361–370

    Article  CAS  PubMed  Google Scholar 

  • Lin SL, Tsai RY, Shen CH, Lin FH, Wang JJ, Hsin ST, Wong CS (2010) Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinflammation in the spinal cords. Pharmacol Biochem Behav 96(2):236–245. doi:10.1016/j.pbb.2010.05.012. Epub 15.05.2010

    Article  CAS  PubMed  Google Scholar 

  • Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. pii: sbw003. 42(5):1262–1269

    Google Scholar 

  • McEvoy JP, Lieberman JA, Stroup TS, CATIE Investigators et al (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163(4):600–610

    Article  PubMed  Google Scholar 

  • Meisenzahl EM, Dresel S, Frodl T et al (2000) D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenamide SPECT study. Psychopharmacology (Berl) 14:364–370

    Article  CAS  Google Scholar 

  • Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159–1172

    Article  CAS  PubMed  Google Scholar 

  • Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res 141(2–3):144–152. doi:10.1016/j.schres.2012.07.029. Epub 04.09.2012

    Article  PubMed  Google Scholar 

  • Messer T, Schmauß M (2006) Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Wien/New York

    Google Scholar 

  • Messer T, Pajonk FG, Müller MJ (2015) Pharmacotherapy of psychiatric acute and emergency situations: general principles. Nervenarzt 86(9):1097–1110. doi:10.1007/s00115-014-4148-x

    Article  CAS  PubMed  Google Scholar 

  • Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ (2010) The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 5(4):E8–E16. doi:10.1002/jhm.691

    Article  PubMed  Google Scholar 

  • Möller HJ (2005a) Antipsychotic and antidepressive effects of second generation antipsychotics. Two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci 255:190–201

    Article  PubMed  Google Scholar 

  • Möller HJ (2005c) Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 255:83–93

    Article  PubMed  Google Scholar 

  • Möller HJ (2005d) Schizophrenie und andere wahnhafte funktionelle Psychosen. In: Bergner M, Hampel H, Möller HJ, Zaudig M (Hrsg) Gerontopsychiatrie. Grundlagen, Klinik und Praxis. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 522–554

    Google Scholar 

  • Möller HJ (2008) Do effectiveness („real world“) studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 258:257–270

    Article  PubMed  Google Scholar 

  • Möller-Leimkühler AM (2006) Mulitvariate prediction of relatives’ stress outcome on year after first hospitalization of schizophrenic and depressed patients. Eur Arch Psychiatry Clin Neurosci 256:122–130

    Article  PubMed  Google Scholar 

  • Morgan CJ, Freeman TP, Powell J, Curran HV (2016) AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry 6:e738. doi:10.1038/tp.2015.219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Müller N, Schwarz MJ (2006) Neuroimmune-endocrine crosstalk in schizophrenia and mood disorder. Expert Rev Neurother 6:1017–1038

    Article  PubMed  Google Scholar 

  • Murray RM, Di Forti M (2016) Cannabis and psychosis: what degree of proof do we require? Biol Psychiatry 79(7):514–515. doi:10.1016/j.biopsych.2016.02.005

    Article  PubMed  Google Scholar 

  • Naber D, Lambert M (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23:649–659

    PubMed  Google Scholar 

  • Naber D, Lambert M, Karow A (2004) Subjektive Befindlichkeit unter neuroleptischer Behandlung und ihre Bedeutung für Compliance und Krankheitsverlauf. Psychiatr Prax 31(Suppl 2):230–232

    Article  Google Scholar 

  • National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia: treatment and management. Clinical guideline 178. http://guidance.nice.org.uk/CG178

  • Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia – a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131(3):185–196. doi:10.1111/acps.12374. Epub 16.01.2015

    Article  CAS  PubMed  Google Scholar 

  • Palm U, Keeser D, Hasan A, Kupka MJ, Blautzik J, Sarubin N, Kaymakanova F, Unger I, Falkai P, Meindl T, Ertl-Wagner B, Padberg F (2016) Prefrontal transcranial direct current stimulation for treatment of schizophrenia with predominant negative symptoms: a double-blind, sham-controlled proof-of-concept study. Schizophr Bull. pii: sbw041. 42(5):1253–61

    Google Scholar 

  • Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A (2015) Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 172(1):52–58. doi:10.1176/appi.ajp.2014.13060787. Epub 31.10.2014

    Article  PubMed  Google Scholar 

  • Pettersson-Yeo W, Allen P, Benetti S, McGuire P, Mechelli A (2011) Dysconnectivity in schizophrenia: where are we now? Neurosci Biobehav Rev 35(5):1110–1124. doi:10.1016/j.neubiorev.2010.11.004. Epub 27.11.2010

    Article  PubMed  Google Scholar 

  • Philip Robson MGP, Cubala WJ, Vasile D, Morrison P, Wright S (2016) A double-blind, randomised, placebo-controlled, parallel group trial of cannabidiol as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder. npj Schizophrenia 2, 16010. doi:10.1038/npjschz.2016.10

    Google Scholar 

  • Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR (2014) Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 152(2–3):325–332

    Article  PubMed  PubMed Central  Google Scholar 

  • Priebe L, Degenhardt F, Strohmaier J et al (2013) Copy number variants in German patients with schizophrenia. PLoS One 8(7):e64035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prüß H (2013) Neuroimmunologie: Neues zur limbischen Enzephalitis. Aktuel Neurol 40:127–136

    Article  Google Scholar 

  • Raine A (2006) Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annu Rev Clin Psychol 2:291–326

    Article  PubMed  Google Scholar 

  • Randall JR, Vokey S, Loewen H, Martens PJ, Brownell M, Katz A, Nickel NC, Burland E, Chateau D (2015) A systematic review of the effect of early interventions for psychosis on the usage of inpatient services. Schizophr Bull 41(6):1379–1386. doi:10.1093/schbul/sbv016. Epub 05.03.2015

    Article  PubMed  PubMed Central  Google Scholar 

  • Rapoport JL, Giedd JN, Gogtay N (2012) Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 17(12):1228–1238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Riedel M, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Sauer H, Schneider F, Gaebel W, Jäger M, Möller HJ, Schennach-Wolff R (2012) Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. World J Biol Psychiatry Jan13(1):30–38

    Google Scholar 

  • Ripke S, O’Dushlaine C, Chambert K et al (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45(10):1150–1159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK (2015) A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41(6):1227–1236

    Article  PubMed  PubMed Central  Google Scholar 

  • Ross K, Freeman D, Dunn G, Garety P (2011) A randomized experimental investigation of reasoning training for people with delusions. Schizophr Bull 37(2):324–333. doi:10.1093/schbul/sbn165. Epub 11.06.2009

    Article  PubMed  Google Scholar 

  • Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):162–167

    Google Scholar 

  • Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64(10):1123–1131

    Article  PubMed  Google Scholar 

  • Saia-Cereda VM, Cassoli JS, Schmitt A, Falkai P, Nascimento JM, Martins-de-Souza D (2015) Proteomics unravel pivotal players in the dysfunction of cell signaling, structure and myelination in schizophrenia brains based in the corpus callosum. Eur Arch Psychiatry Clin Neurosci 265(7):601–612

    Article  PubMed  Google Scholar 

  • Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172(7):617–629. Epub 05.06.2015

    Article  PubMed  Google Scholar 

  • Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, Leucht S (2016) Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73(3):199–210. doi:10.1001/jamapsychiatry.2015.2955

    Article  PubMed  Google Scholar 

  • Saß H (1990) Operationale Diagnostik in der Psychiatrie. Nervenarzt 61:255–258

    PubMed  Google Scholar 

  • Schaeffer EL, Kühn F, Schmitt A, Gattaz WF, Gruber O, Schneider-Axmann T, Falkai P, Schmitt A (2013) Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. J Neural Transm (Vienna) 120(1):187–195

    Article  Google Scholar 

  • Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M (2009) Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res Dec 43(16):1294–1301. doi: 10.1016/j.jpsychires.2009.05.003. Epub 2009 Jun 7

  • Schennach-Wolff R, Möller HJ, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Riedel M. A (2010) Critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Pharmacopsychiatry Nov 43(7):245–251

    Google Scholar 

  • Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Möller HJ (2012) Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial. Psychiatr QJun83(2):187–207

    Google Scholar 

  • Schennach R, Riedel M, Obermeier M, Spellmann I, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ (2015) What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci Mar 265(2):107–116. https://www.ncbi.nlm.nih.gov/pubmed/25261210

  • Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427

    Article  PubMed Central  CAS  Google Scholar 

  • Schmitt GJE, Meisenzahl EM, Frodl T et al (2005) The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. J Psychopharmacol 19:488–493

    Article  CAS  PubMed  Google Scholar 

  • Schmitt GJE, La Fougère C, Dresel S et al (2008) Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naïve schizophrenic patients. Schizophr Res 101:133–141

    Article  CAS  PubMed  Google Scholar 

  • Schmitt A, Steyskal C, Bernstein HG, Parlapani E, Schaeffer EL, Gattaz WF, Bogerts B, Schmitz C, Falkai P (2009) Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 117(4):395–407

    Article  PubMed  Google Scholar 

  • Schmitt A, Hasan A, Gruber O, Falkai P (2011) Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 261(Suppl 2):S150–S154

    Article  PubMed  Google Scholar 

  • Schmitt A, Malchow B, Hasan A, Falkai P (2014) The impact of environmental factors in severe psychiatric disorders. Front Neurosci 8:19

    Article  PubMed  PubMed Central  Google Scholar 

  • Schnack HG, van Haren NE, Nieuwenhuis M, Hulshoff Pol HE, Cahn W, Kahn RS (2016) Accelerated brain aging in schizophrenia: a longitudinal pattern recognition study. Am J Psychiatry 173:607–616

    Google Scholar 

  • Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altamura AC, Murray R, Bhattacharyya S (2016) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3(3):215–225

    Article  PubMed  Google Scholar 

  • Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly MJ, Carroll MC, Stevens B, McCarroll SA (2016) Schizophrenia risk from complex variation of complement component 4. Nature 530(7589):177–183. doi:10.1038/nature16549. Epub 27.01.2016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Selvaraj S, Arnone D, Cappai A, Howes O (2014) Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev 45:233–245. doi:10.1016/j.neubiorev.2014.06.005. Epub 24.06.2014

    Article  CAS  PubMed  Google Scholar 

  • Siris SG (2001) Suicide and schizophrenia. J Psychopharmacol 15(2):127–135

    Article  CAS  PubMed  Google Scholar 

  • Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW (2013) Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 3(4). doi:10.1136/bmjopen-2013-002808. pii: e002808. Print 2013

  • Sommer IE, Slotema CW, Daskalakis ZJ, Derks EM, Blom JD, van der Gaag M (2012) The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr Bull 38(4):704–714

    Article  PubMed  PubMed Central  Google Scholar 

  • Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40(1):181–191. doi:10.1093/schbul/sbt139. Epub 08.10.2013

    Article  PubMed  Google Scholar 

  • Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:f185

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Stefansson H, Meyer-Lindenberg A, Steinberg S et al (2014) CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature 505(7483):361–366

    Article  CAS  PubMed  Google Scholar 

  • Taylor DM, Smith L, Gee SH, Nielsen J (2012) Augmentation of clozapine with a second antipsychotic – a metaanalysis. Acta Psychiatr Scand 125(1):15–24

    Article  CAS  PubMed  Google Scholar 

  • Tienari P (1991) Gene-environment interaction in adoptive families. In: Häfner H, Gattaz WF (Hrsg) Search for the causes of schizophrenia, 2. Aufl. Springer, Berlin/Heidelberg/New York/Tokio, S 126–143

    Google Scholar 

  • Torrey EF, Miller J, Rawlings R, Yolken RH (1997) Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 28(1):1–38

    Article  CAS  PubMed  Google Scholar 

  • Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Carpenter W (2013) Attenuated psychosis syndrome in DSM-5. Schizophr Res 150(1):31–35

    Article  PubMed  PubMed Central  Google Scholar 

  • Van den Oord EJ, Rujescu D, Robles JR, Giegling I, Birrell C, Bukszár J, Murrelle L, Möller HJ, Middleton L, Muglia P (2006) Factor structure and external validity of the PANSS revisited. Schizophr Res 82(2–3):213–223. Epub 17.10.2005

    Article  PubMed  Google Scholar 

  • Van Erp TG, Hibar DP, Rasmussen JM et al (2016) Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry 21(4):547–553

    Article  PubMed  Google Scholar 

  • Van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS (2012) The course of brain abnormalities in schizophrenia: can we slow the progression? J Psychopharmacol 26(5 Suppl):8–14

    Article  PubMed  Google Scholar 

  • Van Os J, Kapur S (2009) Schizophrenia. Lancet 374(9690):635–645. doi:10.1016/S0140-6736(09)60995-8

    Article  PubMed  CAS  Google Scholar 

  • Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14(3):339–347. doi:10.1002/wps.20252

    Article  PubMed  PubMed Central  Google Scholar 

  • Vita A, De Peri L, Silenzi C, Dieci M (2006) Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 82(1):75–88. Epub 27.12.2005

    Article  CAS  PubMed  Google Scholar 

  • Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D (2012) Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 137(1–3):246–250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Watts CA (1985) A long-term follow-up of schizophrenic patients: 1946–1983. J Clin Psychiatry 46(6):210–216

    CAS  PubMed  Google Scholar 

  • Wheeler AL, Voineskos AN (2014) A review of structural neuroimaging in schizophrenia: from connectivity to connectomics. Front Hum Neurosci 8:653

    Article  PubMed  PubMed Central  Google Scholar 

  • Wobrock T, Soyka M (2009) Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opin Pharmacother 10(3):353–367

    Article  CAS  PubMed  Google Scholar 

  • Wobrock T, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A (2015) Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry 77(11):979–988. doi:10.1016/j.biopsych.2014.10.009. Epub 23.10.2014

    Article  PubMed  Google Scholar 

  • Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL, Voisey J (2014) Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry 4:e339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zubin J (1985) Negative symptoms: are they indigenous to schizophrenia? Schizophr Bull 11:461–470

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, LMU München, Nußbaumstr. 7, 80336, München, Deutschland

    Peter Falkai, Rebecca Schennach, Annette Schaub & Alkomiet Hasan

  2. Schön Klinik Roseneck, Am Roseneck 6, 83209, Prien am Chiemsee, Deutschland

    Rebecca Schennach

  3. Fakultät für Psychologie und Bewegungswissenschaft, Institut für Psychologie, Arbeitsbereich KPP, Universität Hamburg, Von-Melle-Park 5, 20146, Hamburg, Deutschland

    Tania Lincoln

Authors
  1. Peter Falkai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca Schennach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tania Lincoln
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annette Schaub
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alkomiet Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Falkai .

Editor information

Editors and Affiliations

  1. em. Direktor der Klinik für Psychiatrie und Psychotherapie, der Ludwig-Maximilians-Universität (LMU) München, München, Germany

    Hans-Jürgen Möller

  2. Ehem. Ärztlicher Direktor des kbo-Inn-Salzach-Klinikums für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Akadem. Lehrkrankenhaus der LMU München Institut für Psychologische Medizin (IPM), Soyen, Germany

    Gerd Laux

  3. Vorstand der Klinik für Psychiatrie und Psychotherapeutische Medizin, Medizinische Universität Graz, Graz, Austria

    Hans-Peter Kapfhammer

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Deutschland

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Falkai, P., Schennach, R., Lincoln, T., Schaub, A., Hasan, A. (2017). Schizophrene Psychosen. In: Möller, HJ., Laux, G., Kapfhammer, HP. (eds) Psychiatrie, Psychosomatik, Psychotherapie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49295-6_64

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49295-6_64

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49293-2

  • Online ISBN: 978-3-662-49295-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation